NEW YORK (360Dx) – Australian proteomics firm Proteomics International said today it is collaborating with Janssen Research & Development to use its PromarkerD test for diabetic kidney disease in drug development.

Under the terms of the agreement, the companies will evaluate the performance of the PromarkerD test for predicting decline in kidney function and drug response in patients from Janssen's clinical trials. The companies will also look at whether PromarkerD is useful for predicting heart disease.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.